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background: Liver injury and portal hypertension are significant complications of the Fontan circulation and are thought to result from chronic 
venous hypertension. The flow characteristics of the involved veins, specifically the hepatic vein (HV), are unknown in this population, and their 
association with clinical outcomes has not been studied. We hypothesize that decreased HV flow is associated with adverse clinical outcomes.
methods: A retrospective review of 58 adult post-Fontan patients referred for an echocardiographic evaluation from 2001 to 2013 was performed. 
The Doppler echocardiographic data was used to estimate the HV flow. The relationship between HV flow per cardiac cycle (HV cross-sectional area 
multiplied by the average velocity time integral per cardiac cycle) and outcome measures, which were features of portal hypertension (VAS score ≥2, 
1 point each for Varices, Ascites, or Splenomegaly) or a major adverse event (death or heart transplant) were examined using multivariable logistic 
regression.
results: 58 post-Fontan patients (79.3% systemic left ventricle, mean age 29.3 ± 8.2 years, mean interval from Fontan 22.4 ± 4.8 years) were 
included in analysis. The mean hepatic venous flow per cardiac cycle was 12.1 ± 10.9ml, mean HV diameter was 1.2 ± 0.4cm, and the mean 
anterograde-retrograde HV flow ratio was 2.9 ± 2.3. Features of portal hypertension (VAS score ≥ 2) were present in 14 (24.1%), and there were 
16 (27.6%) major adverse events: death (n = 11) and transplant (n = 8). After adjusting for time since Fontan operation and age, a significant 
relationship was found between HV flow per cardiac cycle and both major adverse events and features of portal hypertension: the estimated odds 
ratio for VAS score ≥ 2 comparing 25th percentile to 50th percentile of HV flow was 2.29 [95% CI 1.06-4.93, p=0.034], and that for death and need 
for transplant was 2.16 [95% CI 1.00-4.64, p=0.049].
conclusions: Hepatic venous flow is a novel echocardiographic marker associated with major clinical adverse outcomes in Fontan patients. Future 
prospective studies are needed to establish the reproducibility and predictability of this novel marker.
